1. Barragan P, Podzamczer D. Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment. Expert Opin Pharmacother. 2008 Sep;9(13):2363-75. https://doi.org/10.1517/14656566.9.13.2363
2. Croxtall JD, Perry CM. Lopinavir/Ritonavir: a review of its use in the management of HIV-1 infection. Drugs. 2010 Oct 1;70(14):1885-915. https://doi.org/10.2165/11204950-000000000-00000
3. Drugs.com. Lopinavir. 2021. https://www.drugs.com/international/lopinavir.html
4. Drugs.com. Lopinavir / ritonavir Pregnancy and Breastfeeding Warnings. 2021. https://www.drugs.com/pregnancy/lopinavir-ritonavir.html
5. Badan Pengawas Obat dan Makanan. Pusat Informasi Obat Nasional: Lopinavir/Ritonavir. 2022. http://pionas.pom.go.id/monografi/lopinavir-ritonavir
13. Cek Produk BPOM. Lopinavir. 2022. https://cekbpom.pom.go.id//home/produk/nfd2v56aamotmr9s9tg9pveo90/all/row/10/page/1/order/4/DESC/search/5/lopinavir
14. Kanters S, Socias ME, et al. Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis. Lancet HIV. 2017 Oct;4(10):e433-e441.
15. Huang Y, Huang X, et al. Assessing the Efficacy of Lopinavir/Ritonavir-Based Preferred and Alternative Second-Line Regimens in HIV-Infected Patients: A Meta-Analysis of Key Evidence to Support WHO Recommendations. Front Pharmacol. 2018 Aug 14;9:890.
16. Cahn P, Andrade-Villanueva J, et al. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Lancet Infect Dis. 2014 Jul;14(7):572-80.
17. Hakim JG, Thompson J, et al. Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial. Lancet Infect Dis. 2018 Jan;18(1):47-57.